University of North Carolina at Chapel Hill- CGIBD — Chapel Hill, North Carolina

University of North Carolina at Chapel Hill- CGIBD is a clinical research site located in Chapel Hill, North Carolina, United States 27514.

Crixeo Clinical Trials Trust Score: 90/100 (GOOD). This profile has not yet been claimed by the site owner.

University of North Carolina at Chapel Hill- CGIBD has participated in 1 clinical trials.

Therapeutic areas: Inflammatory Bowel Diseases, Crohns Disease, Ulcerative Colitis.

Sponsors: University of North Carolina, Chapel Hill.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chapel Hill

Browse all research sites in North Carolina · View every site in Chapel Hill

Sponsor Feasibility Report

Trust Score: 90/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of North Carolina at Chapel Hill- CGIBD?

University of North Carolina at Chapel Hill- CGIBD has a Crixeo Trust Score of 90/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of North Carolina at Chapel Hill- CGIBD conducted?

University of North Carolina at Chapel Hill- CGIBD has 1 clinical trials on record. Their work covers Inflammatory Bowel Diseases, Crohns Disease, Ulcerative Colitis.

Is University of North Carolina at Chapel Hill- CGIBD accredited by Crixeo Clinical Trials?

University of North Carolina at Chapel Hill- CGIBD has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of North Carolina at Chapel Hill- CGIBD?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.